Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
IMGN ImmunoGen
4.580
-0.120-2.55%
Post Mkt Price
4.5800.0000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Assets
Current assets
Cash, cash equivalents and short term investments
56.08% 373.87M 54.58% 437.66M 62.92% 478.75M 62.92% 478.75M
-Cash and cash equivalents
56.08% 373.87M 54.58% 437.66M 62.92% 478.75M 62.92% 478.75M
Receivables
-70.76% 5.95M -51.26% 10.25M -38.09% 13.93M -- --
-Accounts receivable
12885.71% 909K 1179.57% 1.19M 12662.86% 4.47M -- --
-Other receivables
-75.22% 5.04M -56.73% 9.06M -57.88% 9.46M -- --
Prepaid assets
-2.79% 14.1M -42.89% 8.81M -7.33% 7.32M -- --
Total current assets
43.56% 393.92M 42.92% 456.72M 54.2% 500M 62.92% 478.75M
Non current assets
Net PPE
-13.59% 15.7M -14.4% 16.32M -14% 17.06M -- --
-Gross PPE
-13.59% 15.7M -14.4% 16.32M -1.79% 46.74M -- --
-Accumulated depreciation
-- -- -- -- -6.93% -29.69M -- --
Other non current assets
42.65% 12.68M 18.39% 8.67M -20.71% 8.71M -23.2% 47.02M
Total non current assets
4.89% 28.37M -5.3% 24.99M -16.39% 25.77M -23.2% 47.02M
Total assets
40.09% 422.3M 39.24% 481.71M 48.07% 525.77M 48.07% 525.77M
Liabilities
Current liabilities
Payables
48.27% 17.25M 24.34% 16.06M 93.27% 18.43M -- --
-accounts payable
48.27% 17.25M 24.34% 16.06M 93.27% 18.43M -- --
Current accrued expenses
25.37% 36.59M -12.46% 28.73M -21.32% 23.04M -- --
Current debt and capital lease obligation
-9.92% 3.87M -27.83% 3.76M -32.49% 3.54M -- --
-Current capital lease obligation
21.09% 3.87M 20.69% 3.76M 12.43% 3.54M -- --
Current deferred liabilities
-70.93% 15.64M -54.54% 23.42M 51.63% 44.35M 51.63% 44.35M
Other current liabilities
-50.76% 8.77M -69.87% 8.74M -86.3% 6.08M -39.19% 56.59M
Current liabilities
-27.63% 87.07M -37.39% 84.12M -17.48% 100.95M -17.48% 100.95M
Non current liabilities
Long term debt and capital lease obligation
-21.92% 13.25M -20.22% 14.26M -18.27% 15.24M -- --
-Long term capital lease obligation
-21.92% 13.25M -20.22% 14.26M -18.27% 15.24M -- --
Non current deferred liabilities
-21.39% 43.61M -20.21% 46.69M -40.99% 47.72M -40.99% 47.72M
Other non current liabilities
-29.05% 28.53M -26.58% 30.17M -16.93% 36.27M -17.33% 51.52M
Total non current liabilities
-24.2% 85.39M -22.44% 91.12M -30.69% 99.23M -30.69% 99.23M
Total liabilities
-25.98% 172.46M -30.42% 175.24M -24.6% 200.18M -24.6% 200.18M
Shareholders'equity
Share capital
10.13% 2.21M 10.31% 2.21M 13.03% 2.2M -- --
-common stock
10.13% 2.21M 10.31% 2.21M 13.03% 2.2M -- --
-Preferred stock
-- 0 -- 0 -- 0 -- --
Retained earnings
-11.5% -1.56B -9.47% -1.5B -10.46% -1.47B -- --
Paid-in capital
23.36% 1.8B 23.42% 1.8B 26.42% 1.79B -- --
Total stockholders'equity
264.9% 249.83M 225.61% 306.47M 263.5% 325.59M 263.5% 325.59M
Total equity
264.9% 249.83M 225.61% 306.47M 263.5% 325.59M 263.5% 325.59M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.
CEO: Mr. Mark Joseph Enyedy
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...